Curex Safety, Regulation & Compliance: An Independent Review

What Is Curex and How Does It Operate?

Curex markets itself as a telehealth-first platform that connects patients with licensed prescribers for GLP-1 weight-loss medications. The company is cash-pay, meaning insurance reimbursement is typically not involved, and patients interact with prescribers asynchronously or via short video visits before a prescription is generated and routed to an affiliated pharmacy.

The business model is common across the telehealth weight-loss space. Platforms like Curex act as front-ends: they handle intake, matching, and payment, while contracted prescribers and separate pharmacies bear the clinical and dispensing responsibilities. This structure is legal but creates layered accountability that patients should understand before enrolling.

How Prescribers Are Involved

Curex does not employ prescribers directly as salaried clinicians in the traditional sense. Affiliated prescribers hold state licenses and operate under the oversight of their respective state medical boards. The quality of the clinical encounter, including how thoroughly a prescriber reviews contraindications, varies by individual clinician and is not uniformly verifiable from outside the platform.

The Role of the Affiliated Pharmacy

Compounded medications dispensed through telehealth platforms must come from pharmacies registered with the FDA as 503A or 503B facilities. A 503B outsourcing facility operates under current good manufacturing practice (cGMP) standards and is subject to FDA inspection. A 503A compounding pharmacy operates under state-board oversight with less federal scrutiny. The distinction matters for quality assurance, and patients should ask which category applies to any compounded product they receive.

Is Curex Legitimate? Regulatory and Legal Standing

Curex operates legally as a telehealth intermediary. The prescribers it works with must hold valid DEA and state licenses. The platform itself is not a licensed pharmacy and does not manufacture drugs. From a structural standpoint, it resembles other telehealth platforms in the GLP-1 space such as Hims & Hers Health, Ro, and LifeMD.

Legitimacy is not the same as clinical best practice. A platform can be legally compliant while still having inadequate intake screening, insufficient follow-up protocols, or reliance on compounders that have had quality lapses.

FDA Oversight of GLP-1 Medications

The two most-prescribed GLP-1 receptor agonists for weight loss are semaglutide (Wegovy, approved June 2021 at 2.4 mg weekly) and tirzepatide (Zepbound, approved November 2023). Both are FDA-approved and manufactured by Novo Nordisk and Eli Lilly, respectively. Their safety profiles are established in large randomized controlled trials and confirmed in post-marketing surveillance.

Compounded versions are a different matter. During the 2022-2024 drug shortage period, the FDA exercised enforcement discretion allowing 503A and 503B pharmacies to compound semaglutide. In May 2025, the FDA officially removed semaglutide from its shortage list, which legally terminated the right of 503B outsourcing facilities to produce new bulk compounded semaglutide. 503A pharmacies may continue to compound for individual patient prescriptions under specific conditions, but the field has narrowed considerably.

Platforms that continued marketing compounded semaglutide after May 2025 without clear disclosure of this regulatory shift raised legitimate compliance questions.

What the FDA Has Said Directly

The FDA's published guidance states: "FDA has determined that semaglutide is no longer in shortage. Outsourcing facilities and pharmacies that compound semaglutide should be aware of their obligations under federal law." [1] Patients using any telehealth platform that prescribes compounded semaglutide after this date should ask their prescriber for explicit written confirmation that the product is sourced from a compliant facility.

Curex Prescribing Practices: Clinical Appropriateness

Eligibility Criteria That Should Apply

The FDA-approved labeling for Wegovy (semaglutide 2.4 mg) specifies use in adults with an initial BMI of 30 kg/m2 or greater, or 27 kg/m2 or greater in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. [2] The same threshold applies to Zepbound (tirzepatide). A prescriber who bypasses these criteria is operating outside approved labeling.

STEP-1 (N=1,961), the key trial for semaglutide 2.4 mg, enrolled adults with a mean BMI of 37.9 kg/m2 and demonstrated 14.9% mean weight loss at 68 weeks versus 2.4% with placebo (P<0.001). [3] Patients below the approved BMI thresholds were not studied and should not receive these medications.

Contraindications Prescribers Must Screen For

Any clinician prescribing a GLP-1 receptor agonist should screen for:

• Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2), which are absolute contraindications listed in the Wegovy and Zepbound prescribing information
• Active or history of pancreatitis
• Severe gastrointestinal disease
• Pregnancy or planned pregnancy within the treatment period
• Current use of insulin secretagogues (sulfonylureas) that could increase hypoglycemia risk

An asynchronous or very short telehealth intake that does not systematically check these contraindications represents a clinical safety gap, regardless of platform.

Dose Titration and Monitoring

Both semaglutide 2.4 mg and tirzepatide follow mandatory escalation schedules to minimize gastrointestinal adverse effects. Semaglutide starts at 0.25 mg weekly and escalates over 16-20 weeks to the 2.4 mg maintenance dose. Tirzepatide starts at 2.5 mg weekly. A prescriber who skips titration steps to accelerate results, or who prescribes a higher dose than approved, increases a patient's risk of nausea, vomiting, and in rare cases more serious complications.

The Endocrine Society's 2023 Clinical Practice Guideline on Obesity Pharmacotherapy states: "Dose escalation should follow the schedule in the prescribing information; faster escalation is associated with higher rates of discontinuation due to adverse effects." [4]

Compounded Semaglutide: The Central Safety Risk

This is where the safety discussion becomes most concrete. No compounded drug undergoes FDA pre-market review for safety, efficacy, or manufacturing quality the way a branded drug does. Compounded semaglutide is not bioequivalent-tested against Wegovy.

Documented Quality Failures

The FDA's 2024 inspections of 503B outsourcing facilities found manufacturing deviations at multiple sites, including sub- and super-potent dosing and sterility concerns. [5] The Institute for Safe Medication Practices (ISMP) published reports of patients receiving ten-fold dosing errors from compounded semaglutide, primarily due to concentration mismatches between what was labeled and what patients were drawing up from vials. [6]

The Tirzepatide Compounding Question

Tirzepatide was listed on the FDA shortage list through most of 2024. As of mid-2025, its shortage status remains subject to ongoing FDA review. Any platform prescribing compounded tirzepatide should be transparent about current shortage status, because compounding is only permissible while the drug remains on the shortage list.

Questions to Ask Before Filling a Compounded Prescription

1. Is the pharmacy a 503A or 503B facility?
2. Has the pharmacy undergone an FDA inspection in the past 24 months, and what were the findings?
3. What is the exact concentration of semaglutide or tirzepatide in the vial, and what volume delivers the prescribed dose?
4. Is the product tested by a third-party lab for potency and sterility?

Patients who cannot get clear answers to all four questions from their telehealth platform should consider switching to a branded product or a different provider.

Clinical Outcomes: What the Evidence Actually Shows

No peer-reviewed, independently published cohort study of Curex patients exists as of mid-2025. Clinical claims on the Curex website should be read as marketing. The underlying drug efficacy data comes from trials of branded agents, not from Curex's own patient population.

What the Trials Show for the Drugs, Not the Platform

• STEP-1 (N=1,961): semaglutide 2.4 mg, 14.9% mean weight loss at 68 weeks vs. 2.4% placebo [3]
• SURMOUNT-1 (N=2,539): tirzepatide 15 mg, 20.9% mean weight loss at 72 weeks vs. 3.1% placebo (P<0.001) [7]
• SCALE Maintenance (N=422): patients who lost weight on a low-calorie diet then maintained more weight loss on liraglutide 3 mg vs. Placebo at 56 weeks [8]

These are the outcomes that are possible with proper patient selection, correct dosing, and ongoing monitoring. A telehealth platform that does all of those things well could produce similar results. One that does not may produce worse outcomes or more adverse events.

Discontinuation Rates Matter

In STEP-1, 7.0% of semaglutide patients discontinued due to adverse events vs. 3.8% of placebo patients. Gastrointestinal events were the primary driver. A platform without a strong follow-up system to catch early adverse effects and adjust dosing may see higher discontinuation rates and potentially more serious events going unreported.

Curex vs. Alternatives: A Compliance-Focused Comparison

The telehealth GLP-1 space includes several large platforms. From a regulatory-compliance standpoint, the key differentiators are:

Branded vs. Compounded Prescribing

Platforms that exclusively prescribe branded Wegovy or Zepbound through accredited specialty pharmacies carry lower product-quality risk. The trade-off is cost: branded Wegovy lists at approximately $1,349/month without insurance, while compounded semaglutide on telehealth platforms has been priced at $200-400/month.

Platforms that offer both should clearly disclose when a patient is receiving a compounded product. Lack of that disclosure is a compliance concern regardless of the platform's name.

Synchronous vs. Asynchronous Care

Platforms that require a synchronous video visit before prescribing allow prescribers to assess patients more thoroughly than asynchronous text-based intake alone. The American Telemedicine Association recommends that initial prescribing encounters for Schedule-eligible medications include synchronous evaluation. [9] While GLP-1 medications are not controlled substances, the complexity of contraindication screening argues for a similar standard.

Follow-up Structure

Evidence-based obesity management includes regular follow-up to assess weight response, side effects, and metabolic markers. The Obesity Medicine Association recommends follow-up at 4 weeks after initiation and every 12 weeks thereafter at minimum. [10] Platforms that offer automated check-ins only, without access to a prescriber for dose adjustments, fall short of this standard.

Patient Safety: Practical Steps If You Use Any GLP-1 Telehealth Platform

Regardless of which platform a patient chooses, the following steps reduce risk.

Before Starting

Confirm your BMI meets the approved threshold (30 kg/m2, or 27 kg/m2 with a comorbidity). Disclose all current medications, particularly insulin, sulfonylureas, and any drugs that affect gastric emptying. Ask explicitly whether your prescription will be for a branded or compounded product. Request the pharmacy name and verify its accreditation through NABP's website.

During Treatment

Keep a log of adverse effects. Nausea, vomiting, and injection-site reactions are common and usually manageable with slower titration. Persistent severe abdominal pain that radiates to the back is a warning sign of pancreatitis and requires immediate evaluation. The Wegovy prescribing information notes a small signal for acute pancreatitis in post-marketing data; the absolute risk remains low but real. [2]

Reporting Problems

Adverse events from any prescription drug, compounded or branded, can and should be reported to FDA MedWatch at FDA MedWatch. Prescriber conduct concerns should be reported to the relevant state medical board. These reporting mechanisms exist precisely because post-market surveillance depends on patient reports.

Regulatory Outlook: What Is Changing in 2025 and Beyond

The FDA's removal of semaglutide from the shortage list in May 2025 is the single largest regulatory shift affecting GLP-1 telehealth platforms this year. Platforms that built their business on compounded semaglutide volumes must now either transition patients to branded products, source from 503A pharmacies under individual-patient exemptions, or document a legitimate clinical reason (such as a specific allergy to an excipient in Wegovy) for continuing to compound.

The FTC has also increased scrutiny of telehealth marketing claims. Platforms that advertise guaranteed weight-loss outcomes or use patient testimonials without adequate disclosure of typical results risk enforcement action under Section 5 of the FTC Act. [11]

State legislatures in several states, including Florida and Texas, passed telehealth prescribing reforms in 2024 that tightened synchronous-visit requirements for new prescriptions. Platforms operating nationally must track this patchwork of state law.

The net effect is that the regulatory environment for GLP-1 telehealth platforms has become materially stricter over the past 12 months. Platforms that adapted early by pivoting to branded products and synchronous care are better positioned. Platforms that have not are carrying elevated legal and clinical risk.